title: [Medical treatment for experimental retinal vein occlusion--thrombolytic effect of nasaruplase].
abstract: The anti-thrombolytic effect of urokinase (UK), nasaruplase, and argatroban was studied using an experimental rabbit model of retinal vein occlusion (RVO). Experimental RVO was induced by transadventitial thrombin instillation. Five or fourteen days after thrombin application, the rabbits were injected with gelatin-fluorescein sodium and their eyeballs were enucleated for microscopic observation and flat preparation of the retina. Occlusion of retinal vessels was found to be less in number and distribution in the nasaruplase group than in the control group. On microscopic observation, the retinal arteries and veins of the nasaruplase group showed a vascular subendothelial space formation which suggested a process of thrombogenesis and thrombolysis in the space. The coefficiency of beraprost sodium, aspirin, and ozagrel hydrochloride to UK therapy was studied, but there was no significant difference between these groups and the control group with no after-treatment (the UK group). This result shows the effectiveness of nasaruplase for the thrombolytic therapy of RVO.
authors.affiliation: Department of Ophthalmology, Hirosaki University School of Medicine, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Suzuki
authors.forename: M
authors.initials: M
authors.lastname: Matsumoto
authors.forename: C
authors.initials: C
authors.lastname: Katoh
authors.forename: H
authors.initials: H
authors.lastname: Mizutani
authors.forename: T
authors.initials: T
authors.lastname: Sakuraba
authors.forename: H
authors.initials: H
authors.lastname: Yoshimoto
mesh_terms: D000818:Animals; D010960:Plasminogen Activators / Q000627:therapeutic use*; D011817:Rabbits; D012170:Retinal Vein Occlusion / Q000188:drug therapy*; D015912:Thrombolytic Therapy; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
chemical_list: C093687:nasaruplase; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator